REGENERON
Live / Allowed — First extension granted (statement of use) (as of 20 Apr 2026)
What this means for you
Approved and waiting on proof of use. It will register unless the applicant drops it, and its 23 May 2025 filing date already counts against anyone who files later.
Record
- Serial number
- 99199652
- Mark type
- Word mark
- Filed
- 23 May 2025
- Published for opposition
- 26 Aug 2025
- Attorney of record
- Jeffrey J. Scepanski
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances for the treatment and/or prevention of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; genetically modified cells, genome editing reagents, and biological preparations, namely, viral vectors, all for the treatment and/or prevention of diseases, namely, genetic diseases, diseases of the immune system, infectious diseases, autoimmune diseases, and cancer; pharmaceutical preparations for immunotherapy treatment, cell therapy, nucleic acid therapy, and gene therapy
Owner
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
- Regeneron Pharmaceuticals, Inc., Tarrytown, NY, US
Prosecution history
- 20 Apr 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 20 Apr 2026 — SOU EXTENSION 1 GRANTED
- 20 Apr 2026 — SOU EXTENSION 1 FILED
- 20 Apr 2026 — SOU TEAS EXTENSION RECEIVED
- 21 Oct 2025 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 26 Aug 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 26 Aug 2025 — PUBLISHED FOR OPPOSITION
- 20 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 25 Jul 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 25 Jul 2025 — ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
- 25 Jul 2025 — TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
- 18 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 15 Jul 2025 — ASSIGNED TO EXAMINER
- 30 Jun 2025 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 30 Jun 2025 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED